Journal Article DZNE-2021-00128

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
LifeTime and improving European healthcare through cell-based interceptive medicine.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2020
Nature Publ. Group78092 London [u.a.]

Nature <London> 587(7834), 377 - 386 () [10.1038/s41586-020-2715-9]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.

Keyword(s): Artificial Intelligence (MeSH) ; Cell- and Tissue-Based Therapy (MeSH) ; Delivery of Health Care: ethics (MeSH) ; Delivery of Health Care: methods (MeSH) ; Delivery of Health Care: standards (MeSH) ; Delivery of Health Care: trends (MeSH) ; Early Diagnosis (MeSH) ; Education, Medical (MeSH) ; Europe (MeSH) ; Female (MeSH) ; Health (MeSH) ; Humans (MeSH) ; Legislation, Medical (MeSH) ; Male (MeSH) ; Medicine: methods (MeSH) ; Medicine: standards (MeSH) ; Medicine: trends (MeSH) ; Pathology (MeSH) ; Single-Cell Analysis (MeSH)

Classification:

Note: ISSN 1476-4687 not unique: **3 hits**.

Contributing Institute(s):
  1. United epigenomic platform (Schultze - PRECISE)
Research Program(s):
  1. 342 - Disease Mechanisms and Model Systems (POF3-342) (POF3-342)

Appears in the scientific report 2020
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Chemical Reactions ; Clarivate Analytics Master Journal List ; Current Contents - Agriculture, Biology and Environmental Sciences ; Current Contents - Life Sciences ; Current Contents - Physical, Chemical and Earth Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 60 ; Index Chemicus ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
BN DZNE-R&D PRECISE
Public records
Publications Database


Linked articles:

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Erratum/Correction)  ;  ;  ; et al
Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine.
Nature <London> 592(7852), E8 - E8 () [10.1038/s41586-021-03287-8] pmc   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS


 Record created 2021-03-29, last modified 2023-09-15